Soluble amyloid precursor protein a (sAPPa), a secreted proteolytic fragment of nonamyloidogenic amyloid precursor protein (APP) processing, is known for numerous neuroprotective functions. These functions include but are not limited to proliferation, neuroprotection, synaptic plasticity, memory formation, neurogenesis, and neuritogenesis in cell culture and animal models. In addition, sAPPa influences amyloid-b (Ab) production by direct modulation of APP b-secretase proteolysis as well as Abrelated or unrelated tau pathology, hallmark pathologies of Alzheimer's disease (AD). Thus, the restoration of sAPPa levels and functions in the brain by increasing nonamyloidogenic APP processing and/or manipulation of its signaling could reduce AD pathology and cognitive impairment. It is likely that identification and characterization of sAPPa receptors in the brain, downstream effectors, and signaling pathways will pave the way for an attractive therapeutic target for AD prevention or intervention. V C 2016 Wiley Periodicals, Inc.
More than 100 years have passed since Alois Alzheimer and Oskar Fisher's discovery of the two neuropathological hallmarks of Alzheimer's disease (AD), deposition of extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs). Currently, AD is the most common type of age-associated dementia, and there are no disease-modifying treatments. The pathological features of AD are currently known to include 1) extracellular amyloid plaques composed largely of amyloid-b (Ab) peptides (Hardy and Allsop, 1991) , 2) intracellular NFTs composed of the hyperphosphorylated microtubuleassociated protein tau (Goedert et al., 1991) , 3) dysmorphic synapses, and 4) neuronal loss (Palop and Mucke, 2010) . The proteolytic cleavage of amyloid precursor protein (APP) by two different enzymes, b (also called BACE1)-and g-secretases, is a critical step in AD development. In the nonamyloidogenic pathway, most of the APP is cleaved at the plasma membrane by a-secretase, which precludes Ab formation but produces a large secreted N-terminal ectodomain of APP (sAPPa) of 105-125 kDa and small membrane-bound a-C-terminal fragment (CTF; Haass and Selkoe, 1993) . The membrane-bound a-CTF is cleaved by g-secretase complex, resulting in release of P3 peptide of 3 kDa and AICD (APP intracellular domain). In the amyloidogenic pathway, the remaining uncleaved APP is processed into the endosomal-lysosomal compartments by b-secretase, resulting in soluble sAPPb and membrane-bound b-CTF. The subsequent action of g-secretase on b-CTF produces Ab 40/42 peptides and AICD (Kang et al., 1987) . In addition to a-, b-, and gsecretases cleavage, a recent study identified that APP can be cleaved by the metalloprotease meprin b, generating soluble N-terminally truncated APP (N-APP) and Nterminally truncated Ab 2-X peptide variants, which show increased aggregation potential compared with nontruncated Ab 40 peptides (Jefferson et al., 2011; Bien et al., 2012; Schonherr et al., 2016) . Cleavage of APP by meprin b occurs prior to the endocytosis, and different APP mutants affect the catalytic properties of the enzyme. More specifically, Swedish mutant APP does not undergo this cleavage and is unable to produce this truncated Ab variants. Another study showed that APP can also be cleaved by matrix metalloproteinases such as MT5-MMP, referred to as h-secretase, which releases a long truncated ectodomain (sAPPh) and a membrane-bound CTF, termed CTFh (Willem et al., 2015) . The membranebound CTFh is further cleaved by a-and b-secretases, releasing both a long (Ah-a) and a short (Ah-b) peptide, respectively. The cleavage of h cuts far from the Nterminus of the b-secretase cleavage site and produces fragments (92 or 108 amino acids) that end at either the bor the a-secretase site, respectively (Willem et al., 2015; Fig. 1) .
Several in vitro and in vivo studies have demonstrated the toxic properties of Ab peptides since the first identification of the APP gene in 1987 (Kang et al., 1987; Younkin, 1995) . Administration of Ab peptides (Maurice et al., 1996) , their structural mimetics, and anti-Ab antibodies (Cleary et al., 1995) have supported the deleterious functions of the peptide in terms of promoting cognitive deficits. Like sAPPa, sAPPb has beneficial effects, is soluble in nature, and is secreted extracellularly but lacks 16 amino acids at the C-terminus. The potency of sAPPb is found to be 100 times less than that of sAPPa, measured by its ability to protect hippocampal neurons from excitotoxicity, glucose deprivation, and Ab toxicity (Furukawa et al., 1996b; Barger and Harmon, 1997) . In accordance with this finding, other studies also reported the reduced potency of sAPPb as a neuroprotective fragment (Li et al., 1997; Turner et al., 2003) . Like sAPPa, sAPPb also supports axonal outgrowth (Chasseigneaux et al., 2011) and neural differentiation of human embryonic stem cells (Freude et al., 2011) . In contrast to these effects, sAPPb also causes neuronal cell death by binding to the death receptor 6 (DR6; Nikolaev et al., 2009 ) and does not protect against cell death induced by proteasome inhibitors (Copanaki et al., 2010) . Further study showed that sAPPb fragments are not involved in long-term potentiation (LTP; Taylor et al., 2008) . Perneczky and colleagues (2013) have reported that plasma levels of sAPPb were significantly decreased in AD patients compared with control and frontotemporal dementia (FTD) patients. However, sAPPb levels were increased in cerebrospinal fluid (CSF) of mild cognitive impairment (MCI) patients who had progressed to probable AD compared with control and patients with frontotemporal dementia (FTD).
Unlike sAPPb and Ab, sAPPa has demonstrated neurotrophic and neuroprotective functions. We and others have shown that, in contrast to its neuroprotective effects, sAPPa attenuates Ab pathology by binding to the allosteric site of BACE1 PetersLibeu et al., 2015) . Additionally, sAPPa has been shown to reduce tau hyperphosphorylation by inhibiting BACE1 and glycogen synthase kinase (GSK)-3b activity in cell culture and transgenic PSAPP mouse model (Deng et al., 2015) . Surprisingly, the physiological functions and therapeutic importance of this fragment have received little attention. This Review compiles the physiological functions of sAPPa, especially in the context of AD. It is possible that this is not a complete list of potential sAPPa actions. We believe comprehensive understanding of the sAPPa functions, signaling pathways, and downstream effectors could provide new therapeutic opportunities for effective AD drug development.
MODULATION OF APP PROCESSING AND Ab
CLEARANCE BY SAPPa-RECEPTOR INTERACTION Interaction of LRP1 and sAPPa
The physiological functions of sAPPa have been extensively studied in animal and in cell culture models. Earlier work pointed out the role of sAPPa as an extracellular ligand that modulates APP amyloidogenesis. LRP1 was initially identified as a receptor for APOE (Beisiegel et al., 1989) , which regulates APP and Ab metabolism (Kanekiyo and Bu, 2014) . A study by Kounnas and colleagues (1995) first demonstrated that sAPP binds to the endocytic low-density lipoprotein (LDL) receptor-related protein (LRP1) via the Kunitz-type serine protease inhibitor (KPI) domain. Through the interaction with KPI, the LRP1 receptor enhances internalization of sAPPa into the endosomal and lysosomal compartments. The KPI domain is essential for the sAPPa-LRP1 interaction; the sAPPa695 isoform (lacking the KPI domain) acts as a weak LRP1 ligand. Both LRP1 antagonist (receptor-associated protein [RAP] ) and heparin are able to inhibit the interaction. Interestingly, binding of RAP does not completely inhibit the effect and suggests the presence of receptors other than LRP1. Using LRP1-deficient cell lines, Kounnas and colleagues showed that the binding is dependent on LRP1 receptor (Kounnas et al., 1995) . These data provide evidence that secreted APP is internalized into the cell via the LRP1 receptors and that heparin modulates the binding and internalization of sAPPa. sAPPa does not influence Ab production, so it would be very interesting to determine whether the secreted APP751 could affect generation of Ab through sAPPa-(KPI)-LRP1 interaction. Furthermore, Knauer and coworker (1996) demonstrated that LRP1 is also critical for internalization and generation of Ab by cell-surface (unprocessed) APP751 (containing the KPI domain). The interaction between APP and LRP1 receptor leads to increased trafficking of APP into the amyloidogenic endocytic pathway (Knauer et al., 1996) . Fig. 1 . Diagram of amyloid precursor protein (APP) processing pathways and cleavage products. The nonamyloidogenic APP processing pathway (upper) involves cleavages by a-and g-secretases. Sequential cleavage of APP by a-secretase generates sAPPa and C-terminal fragment C83 (not shown). The subsequent cleavage of C83 by gsecretase complex generates APP intracellular domain (AICD) and a short fragment called P3. The amyloidogenic APP processing pathway (lower) involves cleavages by b-and g-secretases. Cleavage of APP by b-secretase generates sAPPb and C-terminal fragment C99 (not shown). Subsequent cleavage of C99 by g-secretase complex generates toxic species Ab (40 or 42, depends on the cutting site) and AICD. This is termed the amyloidogenic pathway because of the generation and accumulation of Ab species into plaques inside the brain. In addition to a-, b-, and g-secretase cleavage, APP is cleaved by metalloprotease meprin b, generating soluble N-terminal truncated APP (N-APP) or Ab 2-X variants. In addition to meprin b cleavage, the cleavage of APP by several matrix metalloproteinases such as MT5-MMP, referred to as h-secretase, releases a long truncated ectodomain (sAPPh) and a membrane-bound C-terminal fragment (CTF), termed CTFg. The membrane-bound CTFh is further cleaved by a-and b-secretases and releases a long (Ah-a) and a short (Ah-b) peptide, respectively. [Color figure can be viewed at wileyonlinelibrary .com] This finding further supports the data of Kounnas and colleagues (1995) by showing that sAPPa695, which lacks the KPI domain, does not undergo this interaction. To identify the sAPPa receptor specifically, Hoffmann and colleagues (1999) used histidine-tag labeling techniques to identify cell-surface-bound sAPPa. Using immunocytochemistry and surface plasmon resonance spectroscopy, they demonstrated that sAPPa (1 and 10 nM) binds specifically on the cell surface microdomain. In 2000 and subsequent years, Goto and Tanzi (2002) further studied the sAPPa-LRP1 interaction and demonstrated that a minidomain within LRP1, known as the LRP-cluster II region, can bind specifically with the sAPPa-KPI domain. They also showed that inhibition of interaction of KPI and the cluster II region of LRP1 reduces generation of Ab in Chinese hamster ovary cells overexpressing wildtype APP (Goto and Tanzi, 2002) . A recent study suggests that all three isoforms of APP are expressed in brain but that APP695 is the predominant isoform in neurons (Guo et al., 2012a) . This finding suggests that LRP1 may not be an exclusive receptor for sAPPa in the brain. It is plausible that inhibition of the sAPPa-(KPI)-LRP1 interaction forces sAPPa to interact with Ab. A proposed tentative sAPPa-Ab interaction and subsequent clearance by LRP1 receptor is illustrated in Figure 2a . More recently, the Pietrzik group (2016) demonstrated that deletion of mouse LRP1 receptors from endothelium cells of the blood-brain barrier (BBB) significantly elevated soluble Ab 42 in the brain and reduced it in blood plasma. This strongly supports LRP1-mediated clearance of Ab across the BBB (Storck et al., 2016) . It is plausible that sAPPa shuttles Ab to the endothelial LRP1 at the abluminal side and shifts Ab out of the brain to the periphery, as shown in Figure 2b . In accordance with this hypothesis, our group (Darlington et al., 2015) found that sAPPa forms a complex with Ab (corresponding to APP 672-688 region) and thereby enhances phagocytosis by monocytes. In addition, sAPPa enhances scavenger receptor class A (SR-A)-mediated phagocytosis of Ab by microglia (brain) and monocytes (peripheral system), as shown in Figure. 2c. There is a need for further study to prove this hypothesis. On the other hand, Moir and Tanzi (2005) have shown that LRP1-mediated removal of Ab involved in the formation of a complex with Ab and APOE or a2-macroglobulin. They demonstrated that the KPI domain inhibits LRP1-mediated clearance of Ab. Further investigation on sAPPa-LRP1 interaction and subsequent endocytosis of APP will characterize sAPPa-mediated efflux of Ab from the brain.
Interaction of Scavenger Receptor SR-A and sAPPa
The microglial expression of SR-A has been shown to increase in brain injury (Bell et al., 1994) and in microglia surrounding the plaques (Honda et al., 1998) . Santiago et al. (2001) found that activated platelets secrete sAPPa in conditioned media, which competes with both LDL and SR-A receptors. They showed that both sAPPa751 and sAPPa695 equally bind to the SR-A receptor, suggesting that the binding is independent of the KPI domain. Although they found that sAPPa (residues of 191-264) is involved in SR-A binding (Santiago-Garcia et al., 2001) , deletion of the SR-A receptors does not affect the plaque numbers and neurodegeneration in transgenic mice expressing human APP (Huang et al., 1999) . Interestingly, our recent work indicates that sAPPa forms a complex with the Ab 1-16 (corresponding to APP672-688) region, which augments the binding of this heterodimer complex with SR-A receptor. Our conclusion is that scavenger receptor SR-A seems to be crucial for sAPPa-mediated clearance of Ab (Darlington et al., 2015) .
Interaction of Sorting Protein-Related Receptor A and sAPPa
A recent study demonstrated that variation within the two different clusters of intronic sequences of sorting protein-related receptor A (SORLA/LR11/SORL1) is linked to sporadic AD (Rogaeva et al., 2007) . Additional study data showed that overexpression of SORLA decreased production of Ab and vice versa (Rogaeva et al., 2007) . This finding is in good agreement with the reduced expression of SORLA in AD brain (Dodson et al., 2006) . Using fluorescence resonance energy transfer (FRET) assay, Andersen et al. (2006) identified binding sites for APP-SORLA interactions. They showed that two different sites of APP (APP28-123 and APP316-498) bind separately with SORLA (residues of 1044-1526). Using plasmon resonance analysis and analytical ultracentrifugation techniques, the same study demonstrated that carbohydrate-linked (APP316-498) E2 domain of APP binds more favorably than the N-terminal (APP28-123) domain (Andersen et al., 2006) . Because the carbohydratelinked domain (APP316-498) is an integral part of the sAPPa molecule, SORLA may be a plausible neuronal receptor. In agreement with this hypothesis, Hartl and colleagues (2013) have confirmed the sAPPa-SORLA interaction in cultured mouse cortical neurons, showing that sAPPa downregulates cyclin-dependent kinase (CDK) 5 activity by binding with the SORLA receptor. As would be expected, the sAPPa-SORLA interaction increased expression of ORP150, which functions as a protective chaperone (Hartl et al., 2013) . As with SORLA, Gustafsen et al. (2013) showed that sortilin acts as a neuronal receptors for sAPPa695. SORLA and sortilin both bind and mediate internalization of sAPPa into different intracellular compartments. Extracellular 6A domain of sAPPa interacts with sortilin in a pH-dependent manner. Sortilin binds with both neuronal (sAPPa695) and nonneuronal (sAPPa751) isoforms, indicating that the interaction could be independent of the KPI domain (Gustafsen et al., 2013) .
Interaction of APP and of Its Different Domains With sAPPa
Earlier works indicated APP as a cell-surface receptor that interacts with a variety of molecules in the extracellular environment. A recent investigation indicates interaction of sAPPa ectodomain and full-length APP are crucial for neurite outgrowth (Young-Pearse et al., 2008) . More specifically, the authors showed that neurotrophic activity of sAPPa is dependent on the membrane-bound full-length APP. To investigate whether binding of sAPPa to the cell surface receptors is dependent on the membrane-bound (unprocessed) APP and of its homologues APLP1 and APLP2, Reinhard et al. (2013) demonstrated that sAPPa binds to the cell surface on a neuroblastoma cell line, B103, which does not express APP, APLP1, or APLP2. This suggests that binding of sAPPa is independent of full-length APP and of its family members. This finding is in disagreement with the Young-Pearse group (2008), who demonstrated that activity of sAPPa is dependent on the full-length APP. Reinhard et al. (2013) also found that the growth factorlike domain (GFLD) of sAPPa binds to the heparan sulfate proteoglycan (HSPG) at a concentration of 100 nM. They concluded that GFLD binds with heparin and that the E2 domain mediates interaction with the HSPG. Fig. 2 . Diagram presenting functions of APP processing metabolites Ab (red) and sAPPa (green) inside the brain. Membrane-associated APP is processed through nonamyloidogenic or amyloidogenic pathway, resulting in the production of sAPPa (green) or Ab (red), respectively. Depending on the cellular conditions, these two fragments can exist as a monomer and/or a homo-/heterodimer. The interaction of sAPPa and LRP1 receptor may induce internalization of Ab into neuronal cells as an sAPPa/Ab heterodimer. Additionally, we hypothesize that LRP1 can transfer this heterodimer across the blood-brain barrier into the peripheral circulation, which then could be phagocytosed by monocytes (a). We hypothesize that sAPPa could shuttle Ab to the endothelial LRP1 at the abluminal side and remove Ab from brain to the periphery (b). Additionally. SR-A, as another possible receptor expressed on microglia cell surface, may also involved in sAPPamediated Ab clearance by microglia (brain) and monocyte (peripheral system; c). The secreted sAPPa (both N-and C-terminal) fragements bind to their neuron membrane receptor p75 NTR and initiate neurite outgrowth (d). In addition, sAPPa protects neuronal cells by disrupting the dimerization of APP (e). Furthermore, sAPPa can trigger expression of neuroprotective genes (IGF-2 and transthyretin) through NFjB and PI3K/Akt signaling, which provides neuronal outgrowth and survival (f). sAPPa also reduces tau pathology by inhibiting GSK3b and BACE1 activity (h). [Color figure can be viewed at wileyonlinelibrary.com]
Interaction and Effect of Dimerization of APP and Its Homologs (APLP1/APLP2) With sAPPa
APP and other homologs such as APLP1 and APLP2 form homo-and/or heterodimers, which modulate the trafficking of APP into the endocytic compartments. The homodimerization of APP at the plasmamembrane drives it into the endocytic compartments and generates Ab upon cleavage by BACE1 (Scheuermann et al., 2001; Kaden et al., 2008) . While studying the effect of sAPPa, Gralle and others have demonstrated that sAPPa protects neuronal cells by disrupting the dimerization of APP, as shown in Figure 2e (Gralle et al., 2009; Khalifa et al., 2010) . While looking at the binding mechanism, Wang and Ha (2004) demonstrated that heparin binds with the antiparallel dimer of APP. In agreement with the heparin-APP interaction, Gralle and colleagues (2006) demonstrated that heparin induces dimerization of sAPPa in solution at high concentrations. Using single-molecule FRET analysis, they showed that heparan sulfate (HS) induces dimerization of APP, which is crucial for intracellular signaling upon binding with an extracellular ligand (Gralle et al., 2009 ). Previous research indicated that both unprocessed and secreted APP can bind with the heparan sulfate (Williamson et al., 1996) and heparin (Mok et al., 1997) , respectively. In recent years, Dahms and colleagues (2010) extensively investigated the interaction of heparin with the ectodomain of APP. They demonstrated that the heparin and E1 domain interaction is very specific (low dissociation constant [Kd] , indicative of high affinity). In addition to heparin-E1 interaction, the E2 domain of APLP1 can bind with HS chain of HSPG in two different ways. The first mechanism involves the specific binding of E2 domain with the nonreducing end of the highly sulfated HS chain of HSPG. The second mechanism involves the general binding of the E2-HS chain. A different but similar study demonstrated that heparin-induced dimerization of APP is mediated by E1 (subdomains GFLD and CuBD) and regulated by the acidic domain (Hoefgen et al., 2014) . Dahms and colleagues (2015) have further demonstrated that sAPPa brings the E2 domain close to the nonreducing end of HS and that the process is enhanced by heparinase modification. Previous research suggested that the transdimerization of sAPPa or APP-E1 domain is crucial for synaptic functions, which also possess a copper binding domain (D2, CuBD, at amino acids 124-189). While investigating the role of copper on APP dimerization, it was shown that copper induced both cis-and trans-dimerization of APP in vitro (Kd 5 18 nM) and in vivo (Kd 5 100 mM) but that the process is independent of the heparin interaction .
ROLE OF SAPPa IN NEUROPROTECTION
Multiple lines of evidence demonstrate that sAPPa protect neurons against a variety of insults in cell cultures and animal models. Initial studies using rat hippocampal and human cortical neurons showed the protective role of sAPPa against hypoglycemic damage and glutamate mediated neurotoxicity (Mattson et al., 1993) . In addition to these findings, both sAPPa695 and sAPPa751 protect rat hippocampal neurons from iron-mediated oxidative injury and Ab-induced Ca 21 -and free radical-mediated neurotoxicity (Goodman and Mattson, 1994) . These findings indicate that sAPPa regulates calcium homeostasis by inhibiting elevation of intracellular Ca 21 concentrations, the mechanism by which it enhances neuronal survival. further investigated the mechanism through which sAPPa shows the neuroprotective effect on hippocampal neurons. They showed that sAPPa increases the levels of cyclic nucleotides (cGMP) in neuronal cells, which inhibits elevation of cytosolic Ca 21 levels through inhibition of NMDA receptors . In a followup study, the same group showed that elevation of cGMP by sAPPa is dependent on the activation of membrane-bound guanylate cyclase but independent of cytosolic (soluble) guanylate cyclase . Using whole-cell patch-clamp and imaging techniques, Furukawa and colleagues extensively investigated sAPPa-mediated neuroprotective mechanisms in hippocampal neurons, showing that sAPPa (0.11 nM) suppresses neuronal excitability by activating K 1 channels and modulates glutamate neurotoxicity by inhibiting NMDA currents (Furukawa et al., 1996a; Furukawa and Mattson, 1998) .
In addition to neuronal cells, both astrocytes and microglia express all three major forms of APP and process this mostly via the amyloidogenic pathway. The level and magnitude of APP expression by nonneuronal cells (astroglial) is much more subtle than the neuronal cells (neurons). Hence, very few articles have reported the exact role of sAPPa in regulating astroglial functions. Barger and colleagues (1997) showed that sAPPa activates microglial inflammation (Barger and Harmon, 1997) and activation via c-Jun N-terminal kinases (JNK) and p38-MAPK pathways (Bodles and Barger, 2005) . In contrast, a different study showed that primary cytokines such as interleukin (IL)-1a stimulates a-secretase activity and expression of ADAM10 and ADAM17, which enhanced APP processing and sAPPa secretion through the nonamyloidogenic pathway (Bandyopadhyay et al., 2006) . However, the secretion and production of sAPPa are independent of c-JNK pathway but dependent on p38-MAPK pathway. A very recent study showed that inflammatory cytokine (such as tumor necrosis factor-a [TNFa] and IL-1b)-treated astrocytes enhance sAPPa production through nonamyloidogenic processing of APP by increasing membrane fluidity in neuronal cells (Yang et al., 2015) . Further study is needed to clarify the role of sAPPa in activating astroglial cells and subsequent effect on neurons in the brain.
In accordance with the cell culture findings, sAPPa also exerts neuroprotective effects in animal models following CNS injury. Administration of recombinant sAPPa in a rat model reduced hippocampal neuronal deaths against ischemic (Smith-Swintosky et al., 1994) , spinal cord (Bowes et al., 1994) , and traumatic brain injury (TBI; Thornton et al., 2006; Corrigan et al., 2011) . In addition to enhanced neuronal survival, surviving neuronal cells synthesize new proteins, attenuate amyloid pathology, and improve cognition and motor functions in a moderately brain-injured APP knockout (KO) mouse model (Corrigan et al., 2012) . A later study by the same group showed that the heparin binding site of sAPPa (residues of 96-110) protects against TBI (Corrigan et al., 2014) . The cellular receptors and the downstream effectors involving these effects are largely unknown. In brief, the neuroprotective effects of sAPPa could be through the modulation of ion channels and gene expressions . Investigating the neuroprotective functions of sAPPa, several studies showed that sAPPa activates phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt; Cheng et al., 2002; Jimenez et al., 2011; Milosch et al., 2014) , nuclear factor-jB (NF-jB; Guo et al., 1998) , and extracellular signal regulated kinase (ERK; Greenberg et al., 1995; Cheng et al., 2002) and inhibits stress-induced c-JNK signaling (Kogel et al., 2005) . Finally, sAPPa-mediated neuroprotection also involves activation and transcription of different factors and enzymes such as insulin-like growth factor 2, manganese superoxide dismutase, catalase, and transthyretin (Stein et al., 2004; Kogel et al., 2005) .
ROLE OF SAPPa IN LEARNING AND
MEMORY FORMATION Alterations or loss of synapses (Terry et al., 1991) and cognitive decline (DeKosky et al., 1996) have been reported in healthy aging and in neurodegenerative diseases, including but not limited to AD. However, the processes of memory formation in the brain are still largely unknown. Nevertheless, to identify the cognitive impairment, researchers and physicians frequently measure LTP in basic and clinical research. In addition to impaired LTP, hippocampal and cortical studies have shown significant correlation between cognitive impairment and synaptic protein loss, clearly indicating that synapses are critical for memory formation and storage (Winocur et al., 2010) . Many researchers have studied the role of APP in synaptic plasticity and memory formation. Not surprisingly, APP, a key protein in AD development, is highly expressed in the presynaptic terminals and plays a critical role in synaptic functions (Turner et al., 2003) , LTP (Seabrook et al., 1999) , and memory formation (Huber et al., 1997; Mileusnic et al., 2000) . Muller and Zheng's group have independently studied the role of APP and its fragments in synapse formation and correlated these abnormalities with cognitive impairment using several APP mutant mouse models (for review see Aydin et al., 2012; Guo et al., 2012b; Muller and Zheng, 2012) . In addition, Jung and Herms (2012) published a comprehensive review on the role of APP in dendritic spine formation. The details of those studies are beyond the scope of this Review.
Initial studies blocking the extracellular domain of APP with anti-APP antibodies showed behavioral and memory impairment in rat models (Doyle et al., 1990; Huber et al., 1993) . Subsequently, using an APP (KO) hypomorphic mouse models, Muller et al. (1994) and Zheng et al. (1995 Zheng et al. ( , 1996 have demonstrated impaired behavioral functions in rodent models. In contrast to the effects of Ab, APP and its proteolytic fragments, particularly sAPPa, promoted enhanced synaptic plasticity (Ishida et al., 1997; Hick et al., 2015) and memory formation (Bour et al., 2004) . Additionally, the positive correlation between decreased CSF levels of sAPPa and impaired cognitive functions in animal (Anderson et al., 1999) and human (Van Nostrand et al., 1992; Lannfelt et al., 1995; Almkvist et al., 1997 ) studies further suggested a role of sAPPa in cognition. To identify the mechanism, intracerebroventricular (ICV) administration of total sAPP antibodies (combined sAPPa and sAPPb) targeted against the N-APP demonstrated memory deficits in rat models (Doyle et al., 1990; Huber et al., 1993) . To investigate the role of sAPPa in learning and memory formation, recombinant sAPPa (0.5 pg/4 ml/mice; Bour et al., 2004) and its active domain (17 residues of sAPPa; Roch et al., 1994) showed improved spatial memory in mice and memory retention in an aged rats, respectively. In investigating the role of sAPPa in LTP formation, induction of LTP has been shown to be associated with an increased secretion of APP and neural cell adhesion molecule in the dentate gyrus (DG) of a rat model (Fazeli et al., 1993) . Furthermore, to investigate whether sAPPa has a role in synaptic plasticity and spatial memory formation, administration of recombinant sAPPa increased and antibodies against endogenous sAPPa decreased LTP and NMDA transmission in an adult rat model (Taylor et al., 2008) . NMDA receptor activation has been shown to be involved in induction of nitric oxide from arginine, which subsequently increases cGMP and stimulates presynaptic (Arancio et al., 2001 ) soluble guanylyl cyclase (East and Garthwaite, 1991) and protein kinase G (PKG) signaling pathway (Zhuo et al., 1994) . A different study in a drug-induced amnestic mouse model showed that both sAPPa695 and sAPPa751 are equally effective in enhancing memory at low doses (0.05-5,000 pg) and that the effect is independent of its KPI domain (Meziane et al., 1998) . A recent study showed that sAPPa (10 nM) significantly increased protein synthesis at hippocampal synapses through cGMP signaling in an adult Sprague-Dawley rat model that might contribute synaptic plasticity (Claasen et al., 2009) .
The APP KO mouse model exhibits anatomical, synaptic, and behavioral alterations. To investigate the role of APP and of its sAPPa fragment, the Muller group (2007) have deleted the APP locus (APP KO) and replaced it with an sAPPa knockin (KI) gene at the same position, which constitutively expressed secreted sAPPa in the brain. They showed that sAPPa KI mice had improved synaptic plasticity, improved cognition, and a rescue of all the deficits shown by APP KO mice such as reductions in brain and body weight, grip strengths, exploratory impairments, alterations in circadian locomotor activity, and impairment of spatial learning and LTP (Ring et al., 2007) . Interestingly, when sAPPa KI mice were crossed with the APLP2 KO background model, most of the double mutants survived into adulthood. Despite the normal synaptic structure and transmission, these mice showed impaired LTP induction and maintenance coupled with working memory impairment. These findings suggest that sAPPa expression does not compensate for the early developmental abnormalities in APLP2 KO mice and shows excessive nerve growth with widened nerve plates (Weyer et al., 2011) . Contrary to the beneficial role of sAPPa, many authors have reported the increased level of sAPPa in autism studies (Bailey et al., 2008 , Ray et al., 2011 . The role of dysregulated secretion of sAPPa in autism is unknown.
To investigate the effect of sAPPb in APP KO mouse, Li et al. (2010) constructed an sAPPb KI mouse model. They found that secreted sAPPb is highly stable in cell culture and in brain and CSF in this transgenic sAPPb KI mouse model. Most of the offspring of the sAPPb KI and APLP2 KO crossed mice died early. All surviving mice showed normal body weight and grip strength with abnormal nerve plate terminals (Li et al., 2010) . The postnatal lethality of the APP/APLP2 double KO mouse was rescued by crossing sAPPa KI with APLP2-deficient mice that showed impaired LTP function (Weyer et al., 2011) . Because of the postnatal lethality of APP double KO mice, the effect of sAPPa was studied in a conditional APP/APLP2 double KO mice model (Hick et al., 2015) . These mice showed reduced neurite length, dendritic branching, spine density, and spine head size in the hippocampus. The authors also demonstrated that exogenous administration of sAPPa (10 nM), but not sAPPb (even at 50 nM, sAPPb does not show this effect), rescued impairment of LTP and memory deficits in this APP/ APLP2 double conditional KO mouse model (Hick et al., 2015) . These findings suggest that sAPPa has a crucial role in improvement of synaptic plasticity and cognitive impairment in transgenic APP mice. Recently, Muller's group (2016) have published data indicating a rescue of the structural, electrophysiological, and behavioral deficits in APP/PS1DE9 mice using adeno-associated virus (AAV)-mediated expression of sAPPa (Fol et al., 2016) . They concluded that sAPPa activated microglial cells, which might reduce soluble Ab species and plaques by upregulating insulin-degrading enzyme (IDE) and triggering receptor expressed on myeloid cells 2 (TREM2) receptors.
PROLIFERATIVE ROLE OF SAPPa IN NEURITOGENESIS AND NEUROGENESIS
The early expression of APP mRNA (at embryonic day 9.5) in a mouse model underscored the significance of this molecule in nervous system development (Salbaum and Ruddle, 1994) . Moreover, crystal structure and computer modeling studies indicate that sAPPa (residues of 18-350) has a cysteine-rich growth factor-like domain (Rossjohn et al., 1999) and plays a key role in outgrowth and survival of neurons in cell culture studies (Araki et al., 1991; Milward et al., 1992; Qiu et al., 1995; Perez et al., 1997) . In line with these findings, both soluble and membrane-bound APP independently increased neurite outgrowth and branching (Whitson et al., 1990; Milward et al., 1992; Qiu et al., 1995) . In contrast, Young-Pearse and coworkers (2008) demonstrated that sAPPa regulates neurite outgrowth through interaction with full-length APP and integrin-b1 signaling. They concluded that the activity of sAPPa is dependent on the membrane-bound APP. Earlier work indicated that neuritotropic and heparin-binding sites of APP are distinct and that a heparinase-insensitive region is responsible for the effect (Ninomiya et al., 1993) . In a different study, Jin and colleagues (1994) have shown that the neuritotropic activity of sAPPa is located on a stretch of 17 amino acids (residues of 319-335), which includes the RERMS (APP 328-332) sequence. Subsequently, Small and others have shown that interaction of APP and HSPG is critical for neurite outgrowth. To identify the heparin-binding domain in APP, deletion mutation and peptide mapping experiments have revealed four heparin-binding sites in APP. Among the four different binding sites, one site (residues of 96-110 of sAPPa) has more affinity than the other three sites Small et al., 1994 Small et al., , 1999 . Additionally, a delta NL mutation in the APP gene that produces less sAPPa but more sAPPb further supports those findings by showing defective neurite extension (Li et al., 1997) . Both early and recent works showed that sAPPa stimulates proliferation of neural stem cells (NSCs; Hayashi et al., 1994; Ohsawa et al., 1999) , embryonic stem cells (Porayette et al., 2009) , and adult progenitor cells (Caille et al., 2004; Demars et al., 2011) . To investigate the signaling pathways involved in the neurite extensions, one study showed that sAPPa activated MAPK/ERK signaling via activation of NMDA receptors (Gakhar-Koppole et al., 2008) . A recent study demonstrated that both sAPPa and sAPPb were able to enhance axonal growth in cell culture at low (nanomolar) concentrations through early growth response protein 1 signaling (Chasseigneaux et al., 2011) . Ohsawa et al. (2001) identified the extracellular matrix glycoprotein fibulin-1, produced mainly by neurons, as a potential sAPPa binding partner in the brain. The binding of sAPPa and fibulin-1 is dependent on Ca 21 and blocked by an antibody against the N-terminal region of APP. In addition, they showed that the Nterminal region of APP binds to fibulin-1 and prevent sAPP-mediated proliferation of NSCs. Both sAPP and fibulin-1 are secreted in the extracellular environment; the consequence of this interaction demands further study.p75 neurotrophin receptor (p 75NTR ) belongs to a large family of transmembrane molecules of the TNF receptor superfamily. Ligand binding studies indicated the multiple functions of this receptor in regulating axonal growth, neuronal survival, synaptic transmission, and apoptosis (Dechant and Barde, 2002) . Several studies have shown that p 75NTR interacts with full-length APP (Fombonne et al., 2009), Ab (Knowles et al., 2009) , Nterminal APP (APP1-286, EC 50 5 300 nM; Nikolaev et al., 2009) , and sAPPa and sAPPb (Hasebe et al., 2013) .
More specifically, the C-terminal region of sAPPa (residues of 314-612) interacts with p 75NTR (EC 50 150 nM) and induced neurite outgrowth through activation of protein kinase A (PKA) signaling (Hasebe et al., 2013) . These findings suggest that sAPPa (both N-and C-terminal) binds to p75 NTR and initiates neurite outgrowth depending on the nature of binding, as shown in Figure 2d .
ROLE OF SAPPa IN MODULATION OF AD
AND AGING Multiple lines of evidence indicate that altered APP processing leads to an increased production of Ab, which contributes to AD pathologies. Cleavage of APP by a-and g-secretases not only prevents generation of toxic Ab peptides but also produces neuroprotective sAPPa. Multiple lines of evidence indicate that sAPPa regulates the trafficking and processing of APP, which may decrease the risk of developing AD. The role of sAPPa as a modulator of the g-secretase complex came from a study showing that sAPPa reduced the Ab 42 /Ab 40 ratio by modulating the enzyme complex (Hou et al., 2010) . Additionally, modulation of BACE1 by sAPPa reduces generation of Ab and plaques in cell culture and in a transgenic mouse model of AD . In accordance with this finding, Varghese's group confirmed sAPPa as an endogenous inhibitor of BACE1 activity. They demonstrated that sAPPa decrease the enzymatic activity of BACE1 by binding to its allosteric site (PetersLibeu et al., 2015) . In addition, sAPPa, acting through unknown receptors, inhibited BACE1 and GSK3b activity, which reduced tau phosphorylation (Deng et al., 2015) . This study also demonstrated that recombinant human sAPPa increased Ser-9 phosphorylation of GSK3b. Earlier work by Jimenez et al. (2011) demonstrated that GSK3b (Ser-9) phosphorylation decreased significantly in aged (18 months) APP/PS1 mice compared with young (6 months) mice. They also showed that soluble Ab modulates the sAPPa-mediated neuroprotective PI3K/Akt/GSK3b signaling pathway in an aged mouse model, as shown in Figure 2f . This indicated a key role of sAPPa in activation of survival pathway in an aged mouse model. The decreased levels of hippocampal sAPPa coupled with reduced NMDA receptors and impaired LTP function further suggest the importance of this soluble fragment in an aged (24-27 months) rat model. In line with this finding, exogenous administration of sAPPa (100 nM) reduces age-associated deregulation of NMDA receptor function and LTP deficits (Moreno et al., 2015) . Moreover, sAPPa-mediated inhibition of apoptosis and dendritic degeneration via c-JNK pathway further underscores the importance of the fragment in aging studies (Copanaki et al., 2010) .
DIAGNOSTIC VALUE OF SAPPa AS AN AD BIOMARKER Several studies have measured the metabolites of APP cleavage such as sAPPa, sAPPb, and total sAPP (sAPPa and sAPPb together) in AD and other neurodegenerative diseases. The results are inconsistent and contradictory in many cases. The inconsistencies are due partially to the heterogeneity of the disease, inconsistencies in MiniMental Status Examination (MMSE) scores, presence of comorbid conditions, specificity and sensitivity of the assays, cross-reactivity of the antibodies, differences in sampling, and processing and storage of CSF samples. Initial studies (Ghiso et al., 1989; Weidemann et al., 1989) as well as a recent one conducted on patients with MMSE score greater than 20 (Lewczuk et al., 2010 ) demonstrated high CSF levels of sAPPa and sAPPb in patients with CSF findings characteristic of AD. The later study lacks healthy controls and comorbid conditions in the cohort. In contrast, other studies measured a slight or no significant change in total sAPP levels in the CSF of AD patients compared with nondemented controls (Palmert et al., 1990; Hock et al., 1998) . Notably, the antibodies used in early studies failed to demonstrate the difference between sAPPa and sAPPb and so instead measured total sAPP. On the other hand, many recent studies showed no significant changes between the two soluble fragments in AD and nondemented controls (Zetterberg and Blennow, 2008; Rosen et al., 2012; Brinkmalm et al., 2013) . In contrast to these studies, although other studies show significantly decreased levels of total and sAPPa, sAPPb was found to be unchanged in AD patients compared with controls (Prior et al., 1991; Van Nostrand et al., 1992; Sennvik et al., 2000) . In accordance with these findings, patients carrying the Swedish mutation (a double mutation in the APP gene) showed significantly decreased levels of sAPPa in the CSF (Lannfelt et al., 1995) . Significant negative correlations between CSF levels of sAPPa and cognitive impairment have been reported for Swedish mutant AD patients (Almkvist et al., 1997) . More recent work by Kim and colleagues (2009) corroborated this finding, demonstrating that mutations in ADAM10 significantly reduced levels of a-secretase and sAPPa in familial late-onset AD. Although the level of sAPPa was significantly decreased in familial (Swedish mutation) and in moderate-to-severe AD, the levels did not change in the early stage of sporadic AD and mild cognitive impairment. In contrast to sAPPa, the higher level of p-tau181 and the reduced level of Ab 42 serve as a diagnostic marker for AD (Blennow, 2004) . Recently, in addition to sAPPa and sAPPb, full-length soluble APP and sAPP complexes were detected in CSF samples (Cuchillo-Ibanez et al., 2015) . Further investigation will clarify whether full-length sAPP complexes with itself and is falsely measured as sAPPa and/or sAPPb.
Several studies have shown that apoliprotein 4 (APOE4), one of the variants of APOE, may also contribute to the CSF level of sAPPa in AD patients. APOE4, a risk factor for late-onset AD (Harold et al., 2009; Lambert et al., 2009) , transports cholesterol in the brain (Liu et al., 2013) . Most studies have demonstrated that the APOE4 variant increased AD risk, whereas the APOE2 variant decreased the risk of AD (Farrer et al., 1997) . In line with these findings, addition of APOE4 to neuroblastoma SH-SY5Y cells (Cedazo-Minguez et al., 2001 ) and cortical neurons carrying the Swedish mutation cocultured with APOE4 astrocytes showed decreased level of sAPPa generation. Accordingly, sAPPa levels are significantly decreased in AD patients having two APOE4 alleles compared with one APOE4 allele. However, the levels of Ab 42 and sAPPb were found unchanged across other APOE genotypes (Vincent and Smith, 2001 ). This indicates that APOE4 might affect a-secretase cleavage of APP.
APP is involved in multiple physiological functions, and variations in sAPPa generation occur in many different conditions in addition to AD. Reduced CSF concentrations of sAPPa has been reported in other conditions such as cerebrovascular and neurodegenerative diseases (Selnes et al., 2010; Steinacker et al., 2011) , bipolar disorder (Jakobsson et al., 2013) , amyotrophic lateral sclerosis (Steinacker et al., 2011) , and idiopathic normal-pressure hydrocephalus (Miyajima et al., 2013) . The lower levels of sAPPa in other conditions indicate that critical clinical evaluation is necessary to rule out the other conditions. Although many association studies have shown sAPPa as a predictive biomarker, more epidemiological data are needed to generate a robust and standard scale that is diagnostically precise and accurate.
THERAPEUTIC POTENTIAL OF SAPPa
This review summarizes numerous physiological functions of sAPPa, which are (Table I ) disrupted in the AD brain in several ways. These functions include, but are not limited to, neuroprotection (Goodman and Mattson, 1994; Gralle et al., 2009) , neurite outgrowth (Araki et al., 1991; Gakhar-Koppole et al., 2008) , elevation of LTP (Ishida et al., 1997; Hick et al., 2015) , and stimulation and proliferation of neuronal cells (Ohsawa et al., 1999; Demars et al., 2011) and nonneuronal cells (Saitoh et al., 1989; Pietrzik et al., 1998) . In addition, sAPPa directly inhibits b-secretase-mediated proteolysis of APP, thereby reducing generation of Ab . Furthermore, sAPPa also has the potential to reduce tau pathology by inhibiting GSK3b and BACE1 activity as shown in Figure 2h (Deng et al., 2015) . Moreover, both single and multiple low-dose infusion of human umbilical cord blood (Darlington et al., 2013) as well as derived monocytes significantly reduce Ab and b-amyloid plaques and decrease APP processing, reactive microgliosis, and associated astrocytosis and cognitive impairment in the PSAPP AD mouse model . While identifying the mechanism, further studies indicated that cord blood monocytes might have their own a-secretase or activate an endogenous a-secretase enzyme in the PSAPP mouse model. Interestingly, exogenous sAPPa reversed the deficiency of phagocytosis shown by aged blood monocytes (Darlington et al., 2015) . Thus, restoration of sAPPa levels in the brain by shifting the amyloidogenic toward the nonamyloidogenic pathway could ameliorate AD-related amyloid and tau pathology, neuronal loss, and cognitive impairment. Increasing a-secretase activity is therefore an attractive strategy for treatment of AD.
Although sAPPa provides neuroprotection, the only way to increase sAPPa level in the brain is by increasing a-secretase and/or decreasing b-secretase activity. The currently known a-secretase enzymes ADAM10, ADAM17 (TNFa converting enzyme, TACE), and ADAM9 reduce some degree of AD pathology (De Strooper et al., 2010) , but these enzymes have other substrates. Although TACE, ADAM10, and ADAM9 are involved mainly in APP a-secretase cleavage, they also cleave various substrates involved in autoimmune and cardiovascular disease, neurodegeneration, neurodevelopmental disorders, infection, inflammation, and cancer (Arribas and Esselens, 2009; Crawford et al., 2009; Peduto, 2009) . Therefore, TACE and ADAM10 have been therapeutic targets for inflammation, cancer, and inflammationassociated cancer (Saftig and Reiss, 2011) . Recently, dysregulation of ADAM10 activity has been shown to be associated with synaptic deficits in fragile X syndrome (Pasciuto et al., 2015) . Despite the side effects, Fahrenholz and Postina (2006) have listed a variety of ways to enhance sAPPa production, including but not limited to Gprotein-coupled muscarinic agonists, serotonin receptor 5HT4 agonists, neuropeptide pituitary adenylate cyclaseactivating polypeptide, PKC activators, statins, retinoids, and caloric restriction (see also Endres and Fahrenholz, 2010) . In addition, a review by Vincent and Govitrapong (2011) summarized various natural and synthetic compounds such as acitretin, SirT1, statin, epigallocatechin-3 gallate, and, estrogen that are able to stimulate a-secretase activity selectively. They also emphasized that the activation of protein kinase and G-protein-coupled receptors mediated upregulation of a-secretase activity.
It is imperative to identify the sAPPa-mediated signaling pathways and downstream effectors fully before using this fragment in therapeutic applications. Several studies suggest that sAPPa stimulates PI3K/protein kinase C (PKC)/Akt signaling in cell culture and animal models. Furthermore, Endres and Fahrenholz (2012) have summarized the modulation of the a-secretase ADAM10 gene expression by retinoic acid derivatives. They concluded that retinoids decrease generation of toxic Ab and increase neuroprotective sAPPa. Recently, the Varghese group have summarized a review discussing the importance of sAPPa and enhancement of this fragments using many different approaches . They found that one of the a 7 -nicotinic acetylcholine receptor partial agonist, tropisetron, significantly increased sAPPa in cell culture and in a mouse model (Spilman et al., 2014) . The sAPPa fragment is too large to cross the BBB. More research is necessary to identify the small functional unit of sAPPa that crosses the BBB but retains functional properties. It has proved to be quite difficult to obtain a small functional unit of sAPPa, because the function is dependent on the conformational structure of this molecule. Recently, the Varghese group have demonstrated that sAPPa and sAPPb adopt a completely different structure, although they are differ by only 16 amino acid residues at the C-terminus (Peters-Libeu et al., 2015) . Transgenic mice engineered to overexpress sAPPa could be another way to accomplish this function. Currently, only one transgenic mouse line overexpressing human sAPPa is available for AD and autism studies (Bailey et al., 2012) . AAV (Fol et al., 2016) -and lentivirusmediated sAPPa gene delivery into the specific region of the brain could be another strategy to increase expression of this fragment locally.
CONCLUSIONS
The presence of amyloid plaques and NFTs is the pathognomonic feature distinguishing AD from other types of dementia. Currently, AD therapy focuses on the prevention and clearance of b-amyloid plaques and NFTs from the brain. Unfortunately, none of the available strategies has resulted in significant cognitive improvement in clinical trials. We believe that restoration of sAPPa function using this fragment, or a mimetic thereof, in the very early stage of the disease will reduce or prevent cognitive impairment in AD and in other neurodegenerative diseases. 
